Over the past two decades, China has introduced significant changes to drug regulations
through regulatory innovations to accelerate drug review and approvals, keeping in line with …

China has been criticized for the long drug delay for a long time. There was little
understanding of Chinese drug lag formation from the investigational new drug (IND) …

Access to anticancer drugs has been a critical health issue in China for many years. We
retrospectively analyzed the novel anticancer drugs approved in the United States (US) …

Immune checkpoint inhibitors (ICIs) are currently one of the most popular treatment methods
for cancers. Several ICIs have been approved in China and the United States. We created a …

Background Global, randomized clinical trials are extremely complex. Trial start-up is a
critical phase and has many opportunities for delay which adversely impact the study …

Abstract Introduction In China, efforts to qualify innovative medical products for
reimbursement used to be subject to substantial delays after regulatory approval due to …

Background In the past decade, the Chinese drug regulatory system has undergone many
changes. A major reform starting in 2015 has significantly reshaped the regulatory …

Biologics are one of the fastest growing fields in the biomedical industry. Producing these
innovative drugs has proven both technologically and politically challenging, however …

Since the late 1950s, radiopharmaceuticals have been used for diagnosis and treatment in
clinical nuclear medicine in China. Over the decades, China has successfully established a …

In China, child and adolescent pediatricians often face challenges in treating children with
the appropriate medications. Within the last 8 years, the Chinese government has already …